Aug 15, 2016
Reflector outlines the obstacles ahead for Europe's revamped Innovative Medicines Initiative.
Aug 12, 2016
Zika vaccine development is hindered by technical challenges and funding shortfalls, writes Jill Wechsler.
Aug 12, 2016
Pharmaceutical Executive
Analysts examine investment and business factors that shape supply disruptions. Jill Wechsler reports.
Aug 08, 2016
Could the new Vermont Drug Transparency law “lead the US Pharmaceutical industry to an awful end”? Tom Norton reports.
Aug 05, 2016
Having lobbied hard to have Inter Partes Review proceedings (IPRs) enacted, the tech industry may now be regretting what it wished for, write Traci Medford-Rosow and Peter C. Richardson.
Jul 27, 2016
Stakeholders are looking to move up the Prescription Drug User Fee Act timeframe to gain Congressional action before the Obama administration steps down.
Jul 27, 2016
Leela Barham looks at the EU plans for a European patent, and asks where the UK will fit in after Brexit.
Jul 20, 2016
Not yet, says Reflector. But to judge from the European Parliament's latest foray into the subject, there could be plenty of support for such an approach.
Jul 12, 2016
Pharmaceutical Executive
A look at how Europe’s new accelerated drug approval scheme can move existing review pathways to something better—and take a page from the FDA experience as well.
Jul 07, 2016
The long planned for transparency of industry payments to doctors, pharmacists, nurses and others has shone some dappled light on the UK industry, writes Leela Barham.
lorem ipsum